What is Baxter International's market cap?

Baxter International (BAX) has a market capitalization of $11.2B and trades on NYSE.

What is Baxter International's revenue and profitability?

Baxter International generated $11.3B in trailing twelve-month revenue with a net loss of $1.1B, representing a net margin of -9.7%. Gross margin stands at 30.1%. These figures are based on the Q1 2026 filing.

Who are Baxter International's competitors?

Baxter International's key competitors include Becton, Dickinson and Company, Medtronic plc, InfuSystem Holdings, Inc., and others. These companies compete in similar markets and product categories.

Who does Baxter International partner with?

Baxter International's notable partners include Carlyle Group Inc..

What subsidiaries does Baxter International have?

Baxter International's subsidiaries include Hill-Rom Holdings, Inc..

Where is Baxter International headquartered?

Baxter International is headquartered in United States of America and employs approximately 60,000 people. It has been publicly traded since 1961.

Baxter International

BAX

Baxter International Inc. is a global medical technology leader that develops and manufactures a diverse portfolio of essential healthcare products and therapies.

Market cap

$11.19B-22.2%

Revenue$11.3B+5.1%

Net income-$1.1B-96.1%

EPS (diluted)-$2.14-96.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

April 30, 2026

Revenue$2.7BBeat by $85.5M EPS$0.36Beat by $0.05

Read the full report

Next report

Jul 30, 2026 (In 5 days)

Revenue estimate$2.8B

EPS estimate$0.36

Financials

Q1 2026

Income statement

See full

Revenue$2.7B+2.9%

Gross profit$891.0M+3.5%

Operating income$66.0M+13.8%

Net income-$15.0M-112%

EPS (diluted)-$0.03-112%

Balance sheet

See full

Cash & equivalents$2.0B-12.1%

Total debt$224.0M-8.9%

Total equity$6.0B-14.7%

Total assets$19.8B-6.8%

Cash flow

See full

Operating cash flow$213.0M+210%

Valuation & ratios

Valuation

See full

Market cap$11.23B-22.2%

Enterprise value$9.43B-29.4%

P/S1×-0.4×

Profitability

See full

Gross margin30.1%-5.9pp

Operating margin-2.7%—

Net margin-9.7%+62.5pp

Returns & leverage

See full

Return on equity-16.7%-76.7pp

Debt / equity0×0.0×

Current ratio1.9×-0.2×

Segments

By product

See full

Infusion Therapies & Technologies$981.0M-1.3%

Care & Connectivity Solutions$435.0M+1.9%

Drug Compounding$320.0M+30.1%

Advanced Surgery$304.0M+13.4%

Injectables & Anesthesia$301.0M-10.1%

By segment

See full

Medical Products & Therapies$1.3B+1.8%

Healthcare Systems & Technologies$705.0M+0.1%

Pharmaceuticals$621.0M+6.9%

By geography

See full

International$1.3B—

Competitors

By market cap

Abbott$175.17B-20.0%

Medtronic$104.82B-11.1%

Becton, Dickinson and Company$42.2B-19.4%

Baxter International$11.2B-23.4%

Option Care Health, Inc.$3.3B-32.7%

UFP Technologies$1.8B-1.8%

Avanos Medical$1.2B+109%

InfuSystem Holdings$179.6M+43.7%

By revenue growth

UFP Technologies+11.2%

Option Care Health, Inc.+9.3%

Medtronic+8.4%

Abbott+8.1%

Becton, Dickinson and Company+6.4%

Baxter International+5.1%

Avanos Medical+3.9%

InfuSystem Holdings+3.5%

By net margin

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

UFP Technologies11.27%-0.3pp

InfuSystem Holdings5.56%+3.2pp

Becton, Dickinson and Company5.33%-2.1pp

Option Care Health, Inc.3.64%-0.5pp

Baxter International-9.7%-4.5pp

Avanos Medical-10.39%+45.4pp

Profile

Baxter International Inc. is a global medical technology leader that develops and manufactures a diverse portfolio of essential healthcare products and therapies. The company focuses on critical care, surgical innovation, and diagnostic technologies, providing life-sustaining solutions used across the continuum of care from hospitals to home settings. Its value proposition centers on improving patient outcomes through integrated medical systems, advanced pharmaceuticals, and digital health solutions.

Competitive position

A leading global provider of medical supplies and equipment with a significant presence in over 100 countries and a dominant position in IV solutions and infusion technology.

GeographiesGlobal, North America, Europe, Asia-Pacific, Emerging Markets

Customer segmentsAcute Care Facilities, Post-Acute Care Providers, Primary Care Physicians, Home Care Patients

Business modelManufacturing, Direct Sales, Research and Development

SuppliersRaw Material Suppliers, Chemical Manufacturers, Electronic Component Suppliers, Specialized Logistics Providers

CustomersHospitals, Kidney Dialysis Centers, Nursing Homes, Home Healthcare Patients, Government Health Agencies

CountryUnited States of America

Listed1961

Employees60.0K

CEOAndrew Hider

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitebaxter.com

FilingsSEC EDGAR

Ask your AI about Baxter International.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Baxter International's market cap?: Baxter International (BAX) has a market capitalization of $11.2B and trades on NYSE.
What is Baxter International's revenue and profitability?: Baxter International generated $11.3B in trailing twelve-month revenue with a net loss of $1.1B, representing a net margin of -9.7%. Gross margin stands at 30.1%. These figures are based on the Q1 2026 filing.
Who are Baxter International's competitors?: Baxter International's key competitors include Becton, Dickinson and Company, Medtronic plc, InfuSystem Holdings, Inc., and others. These companies compete in similar markets and product categories.
Who does Baxter International partner with?: Baxter International's notable partners include Carlyle Group Inc..
What subsidiaries does Baxter International have?: Baxter International's subsidiaries include Hill-Rom Holdings, Inc..
Where is Baxter International headquartered?: Baxter International is headquartered in United States of America and employs approximately 60,000 people. It has been publicly traded since 1961.